title: Recommendation of rotavirus vaccination and herd effect: a budget impact analysis based on German health insurance data.
abstract: The objective of this study was to assess the budget impact and health effects of introducing rotavirus (RV) vaccination in Saxony, Germany, from a health insurance perspective. Special emphasis is given to the herd effect. We analyzed direct medical and non-medical costs of RV infection for Social Health Insurance between 2007 and 2010 based on 360,000 routine data observations from the AOK PLUS for children below 5 years of age. We compared the actual annual number of RV cases (vaccination scenario) with the number derived from 2005 (no vaccination, base case scenario). The vaccination coverage rate has increased from 5% to 61% between 2007 and 2010. The number of RV cases decreased by 21% from 32,274 in 2007 to 25,614 in 2010. Based on vaccination coverage, the total cost savings per 1,000 children due to RV vaccination was estimated to be 39,686 Euros. The overall share of outpatient costs was 60%. Mean gross cost savings were expected to be 304 Euros per avoided case. The net cost savings were expected to be 19 Euros per avoided case. About 59% of total savings was due to herd protection resulting from increasing vaccine rates. The herd effect per avoided case increased with increasing vaccine coverage. Incidence of RV cases, vaccination costs and days absent from work were sensitive parameters. This retrospective analysis showed that the increase in RV vaccination coverage in Saxony has been budget neutral if not cost saving for sick funds.
authors.affiliation: Fakultät Wirtschaftswissenschaften, Gesundheitsökonomisches Zentrum, TU Dresden, 01062, Dresden, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Karmann
authors.forename: Andrea
authors.initials: A
authors.lastname: Jurack
authors.forename: Daniel
authors.initials: D
authors.lastname: Lukas
mesh_terms: D002017:Budgets; D002675:Child, Preschool; D017046:Cost Savings / Q000191:economics; D003362:Cost-Benefit Analysis; D005858:Germany / Q000453:epidemiology; D017048:Health Care Costs; D006801:Humans; D032521:Immunity, Herd; D007223:Infant; D007348:Insurance, Health; D018803:Models, Economic; D012189:Retrospective Studies; D012401:Rotavirus; D012400:Rotavirus Infections / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control; D022243:Rotavirus Vaccines / Q000191:economics* / Q000627:therapeutic use; D014611:Vaccination / Q000191:economics* / Q000706:statistics & numerical data
chemical_list: D022243:Rotavirus Vaccines